Table 2

VEP and ophthalmological examination in patients on vigabatrin

VEP– P100
No.Age at presentSexVigabatrinLatency (ms)Amplitude (μv)
Dose (mg/kg/day)Duration (months)LEREControl2-150LEREInferenceOphthalmological examinationVigabatrin
 111y 4mM1148599103105 (8)16.3314.06NNCont
 210yM5081125123105 (8)20.0 015.73ABNABNStop
 35y 10mF5071140135105 (8)6.87.8ABNABN, RE-OACont
 49y 10mF2560127133105 (8)25.1127.63ABNNCont
 55y 4mM3648No response (previously abnormal)ABNABNCont
 68y 9mM2544117127105 (8)6.95.96ABNABNCont
 74y 7mF58.843186185105 (8)9.619.5ABNNCont
 83y 4mM4040153145105 (8)11.044.97ABNNCont
 95y 5mM62.540144149105 (8)7.916.84ABNNCont
103y 6mM5033171167105 (8)7.74.9ABNABNStop
113y 3mM79.834112107105 (8)11.5412.05NNCont
1219yF4230200160105 (8)5.106.80ABNNStop
132y 10mF5827111107105 (8)10.311.7NTS changesCont
142y 4mF111251590105 (8)6.80ABNNCont
159yM5024No response (previously abnormal)ABNABNCont
162y 3mF6822189196105 (8)5.612.4ABNNCont
172y 2mM7515203205105 (8)1.27.1ABNNCont
184y 7mM3513137140105 (8)28.327.9ABNNCont
191yM9012133129115 (10)7.13.6ABNNCont
201y 2mM40 9113113115 (10)13.113.3NNCont
211y 7mM62.5 6104105115 (10)23.420.3NNCont
  • N, normal; ABN, abnormal; OA, optic atrophy; Cont, continued; VEP, visual evoked potentials; Stop, stopped; LE, left eye; RE, right eye; TS, tuberous sclerosis.

  • 2-150 Taylor.15